{"Symbol": "ARDX", "AssetType": "Common Stock", "Name": "Ardelyx Inc", "Description": "Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.", "CIK": "1437402", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "400 FIFTH AVENUE, WALTHAM, MA, UNITED STATES, 02451", "OfficialSite": "https://www.ardelyx.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "1669233000", "EBITDA": "-35298000", "PERatio": "None", "PEGRatio": "-0.08", "BookValue": "0.635", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.23", "RevenuePerShareTTM": "1.663", "ProfitMargin": "-0.142", "OperatingMarginTTM": "0.0423", "ReturnOnAssetsTTM": "-0.0555", "ReturnOnEquityTTM": "-0.362", "RevenueTTM": "398234000", "GrossProfitTTM": "288945000", "DilutedEPSTTM": "-0.23", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0.123", "AnalystTargetPrice": "14.7", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "10", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "57.47", "PriceToSalesRatioTTM": "4.192", "PriceToBookRatio": "10.85", "EVToRevenue": "4.116", "EVToEBITDA": "-27.36", "Beta": "0.578", "52WeekHigh": "8.4", "52WeekLow": "3.21", "50DayMovingAverage": "6.69", "200DayMovingAverage": "5.41", "SharesOutstanding": "242974000", "SharesFloat": "220419000", "PercentInsiders": "2.953", "PercentInstitutions": "65.525", "DividendDate": "None", "ExDividendDate": "None"}